My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

150.25 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Charles River Announces Agreement with Singapore General Hospital
From Charles River Laboratories International, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Earnings Scheduled For February 19, 2025
 
Via Benzinga
Analyst Expectations For Charles River's Future
 
Via Benzinga
What Analysts Are Saying About Charles River Stock
 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize. 
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume.
Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below. 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know. 
Via StockStory
Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4
Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP... 
Via StockStory
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
From Charles River
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
This STMicroelectronics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
From Charles River Laboratories International, Inc.
Via Business Wire
This Spotify Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
From Charles River Laboratories International, Inc.
Via Business Wire
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report. 
Via Talk Markets
Topics Economy Stocks / Equities
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Introduces Global Biotech Incubator Program
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at UBS and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why
Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.